Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 1
2006 1
2010 1
2011 1
2015 1
2018 1
2020 4
2021 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.
Mulford DJ, Ramsden D, Zhang L, Michon I, Leifke E, Smith N, Jones HM, Scarpignato C. Mulford DJ, et al. Among authors: michon i. CPT Pharmacometrics Syst Pharmacol. 2023 Apr;12(4):532-544. doi: 10.1002/psp4.12939. Epub 2023 Mar 10. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36896795 Free PMC article.
Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial.
Guery B, Georgopali A, Karas A, Kazeem G, Michon I, Wilcox MH, Cornely OA. Guery B, et al. Among authors: michon i. J Antimicrob Chemother. 2020 Apr 1;75(4):1014-1018. doi: 10.1093/jac/dkz549. J Antimicrob Chemother. 2020. PMID: 31960058 Free article. Clinical Trial.
Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: an open-label Phase IIIb/IV study (PROFILE).
Högenauer C, Mahida Y, Stallmach A, Marteau P, Rydzewska G, Ivashkin V, Gargalianos-Kakolyris P, Michon I, Adomakoh N, Georgopali A, Tretter R, Karas A, Reinisch W. Högenauer C, et al. Among authors: michon i. J Antimicrob Chemother. 2018 Dec 1;73(12):3430-3441. doi: 10.1093/jac/dky368. J Antimicrob Chemother. 2018. PMID: 30260412 Clinical Trial.
A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine.
Kanacher T, Lindauer A, Mezzalana E, Michon I, Veau C, Mantilla JDG, Nock V, Fleury A. Kanacher T, et al. Among authors: michon i. Pharmaceutics. 2020 Dec 8;12(12):1191. doi: 10.3390/pharmaceutics12121191. Pharmaceutics. 2020. PMID: 33302490 Free PMC article.
P-selectin as a candidate target in atherosclerosis.
Molenaar TJ, Twisk J, de Haas SA, Peterse N, Vogelaar BJ, van Leeuwen SH, Michon IN, van Berkel TJ, Kuiper J, Biessen EA. Molenaar TJ, et al. Among authors: michon in. Biochem Pharmacol. 2003 Sep 1;66(5):859-66. doi: 10.1016/s0006-2952(03)00387-3. Biochem Pharmacol. 2003. PMID: 12948867
16 results